Surgical treatment of secondary hyperparathyroidism in patients with chronic kidney disease
https://doi.org/10.29235/1814-6023-2018-15-4-465-482
Abstract
Surgery of patients with secondary hyperparathyroidism in the era of calcimimetics continues to play an important role in selected patients and achieves an efficient control of hyperparathyroidism. Taken together, the results of literature review suggest a clinically significant beneficial effect of surgical parathyroidectomy to decrease the overall and cardiovascular mortality in patients with secondary hyperparathyroidism due to chronic kidney disease. However, the independent randomized controlled trial comparing surgery with medical therapy to clarify the outcome and to improve the quality of life is in need.
About the Author
A. M. Pisarenka
Minsk City Clinical Oncology Dispensary, Minsk
Belarus
Head of the Department
Belarus
Head of the Department
References
1. Gansevoort R. T., Heij B., Stegeman C. A., Charro F. T., Nieuwenhuizen M. G., Zeeuw D., Jong P. E. Trends in the incidence of treated end-stage renal failure in the Netherlands: hope for the future? Kidney International, 2004, vol. 66, pp. S7–S10. https://doi.org/10.1111/j.1523-1755.2004.09202.x
2. National Kidney Foundation. K/DOQI clinical practice guidelines for kidney disease: evaluation, classification, and stratification. American Journal of Kidney Disease, 2002, vol. 39, no. 2, suppl. 1, pp. S1–S246.
3. Coresh J., Astor B. C., Greene T., Eknoyan G., Levey A. S. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third national health and nutrition examination survey. American Journal of Kidney Disease, 2003, vol. 41, no. 1, pp. 1–12. https://doi.org/10.1053/ajkd.2003.50007
4. Chadban S. J., Briganti E. M., Kerr P. G., Dunstan D. W., Welborn T. A., Zimmet P. Z., Atkins R. C. Prevalence of kidney damage in Australian adults: The AusDiab Kidney Study. Journal of the American Society of Nephrology, 2003, vol. 14, suppl. 2, pp. S131– S138. https://doi.org/10.1097/01.asn.0000070152.11927.4a
5. Zemchenkov A. Yu., Tomilina N. A. K/DOQI addresses sources of a chronic renal failure (About the new section of Recommendations of K/DOQI about diagnostics, classification and assessment of weight of chronic diseases of kidneys). Nefrologiya i dializ = Nephrology and Dialysis, 2004, vol. 6, no. 3, pp. 204–220 (in Russian).
6. Bikbov B. T., Tomilina N. A. Condition of replacement therapy of patients with a chronic renal failure in the Russian Federation in 1998–2009 (Report on data of the Russian register of replacement renal therapy). Nefrologiya i dializ = Nephrology and Dialysis, 2011, vol. 13, no. 3, pp. 150–264 (in Russian).
7. Egshatyan L. V. Effectiveness of therapeutic and surgical treatment of a secondary hyperparathyreosis at the patients receiving replacement renal therapy by a program hemodialysis. Ph.D. Thesis. Moscow, 2012. 233 p. (in Russian).
8. Shutov A. M., Serov V. A., Kurzina E. V., Gerdt A.M., Serova D. V. Chronic renal disease and atrial fibrillation in patients with chronic heart failure. Terapevticheskii arkhiv [Therapeutic Archive], 2009, vol. 81, no. 12, pp. 23–26 (in Russian).
9. Petrova N. N. Conception of quality of life in patients at renal replacement therapy. Nefrologiya i dializ = Nephrology and Dialysis, 2002, vol. 4, no. 1, pp. 9–14 (in Russian).
10. Tareeva I. E. (ed.). Nephrology: Manual for physicians. 2nd ed. Moscow, Meditsina Publ., 2000. 688 p. (in Russian).
11. Malluche H., Faugere M. C. Renal bone disease 1990: an unmet challenge for the nephrologist. Kidney International, 1990, vol. 38, no. 2, pp. 193–211. https://doi.org/10.1038/ki.1990.187
12. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. American Journal of Kidney Disease, 2003, vol. 42, suppl. 3, pp. 1–202. doi https://doi.org/10.1016/S0272-6386(03)00905-3
13. Pisoni R. L., Gillespie B. W., Dickinson D. M., Chen K., Kutner M. H., Wolfe R. A. The Dialysis Outcomes and Practice Patterns Study (DOPPS): design, data elements, and methodology. American Journal of Kidney Diseases, 2004, vol. 44, no. 5, suppl. 2, pp. S7–S15. https://doi.org/10.1053/j.ajkd.2004.08.005
14. Regidor D. L., Kovesdy C. P., Mehrotra R., Rambod M., Jing J., McAllister C. J., Wyck van D., Kopple J. D., Kalantar-Zadeh K. Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. Journal of American Society of Nephrology, 2008, vol. 19, no. 11, pp. 2193–2203. https://doi.org/10.1681/asn.2008010014
15. Albright F., Baird P. C., Cope О., Bloomberg E. Studies on the physiology of parathyroid glands. IV Renal complications of hyperparathyroidism. American Journal of the Medical Sciences, 1934, vol. 187, no. 1, pp. 49–64. https://doi.org/ 10.1097/00000441-193401000-00006
16. Borisov A. V., Mordik A. I., Borisova E. V., Ermakova I. P., Il’ina A. N., Rozhinskaya L. Ya., Shestakova M. V., Sazonova N. I., Chernova T. O. A parathyroid function and the mineral density of a bone tissue at the patients with a chronic renal failure who are on treatment by a program hemodialysis. Osteoporoz i osteopatii = Osteoporosis and Bone Diseases, 2004, no. 1, pp. 6–10 (in Russian).
17. Akizawa T., Fukagawa M., Koshikawa S., Kurokawa K. Recent progress in management of secondary hyperpara thyroidism of chronic renal failure. Current Opinion in Nephrology and Hypertension, 1993, vol. 2, no. 4, pp. 558–565. https://doi.org/10.1097/00041552-199307000-00006
18. Boer de I. H., Gorodetskaya I., Young B., Hsu C. Y., Chertow G. M. The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, racedependent, and associated with cardiovascular disease. Journal of American Society of Nephrology, 2002, vol. 13, no. 11, pp. 2762–2769. https://doi.org/10.1097/01.asn.0000034202.91413.eb
19. Levin A., Bakris G. L., Molitch M., Smulders M., Tian J., Williams L. A., Andress D. L. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney International, 2007, vol. 71, no. 1, pp. 31–38. https://doi.org/10.1038/sj.ki.5002009
20. Young E. W., Albert J. M., Satayathum S., Goodkin D. A., Pisoni R. L., Akiba T., Akizawa T., Kurokawa K., Bommer J., Piera L., Port F. K. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney International, 2005, vol. 67, no. 3, pp. 1179–1187. https://doi.org/10.1111/j.1523-1755.2005.00185.x
21. Gasparri G., Camandona M., Abbona G. C., Papotti M., Jeantet A., Radice E., Mullineris B., Dei Poli M. Secondary and tertiary hyperparathyroidism: causes of recurrent disease after 446 parathyroidectomies. Annals of Surgery, 2001, vol. 233, no. 1, pp. 65–69. https://doi.org/10.1097/00000658-200101000-00011
22. Rozhinskaya L. Ya. Secondary hyperparathyreosis and renal osteopathies in patients with chronic renal failure. Nefrologiya i dializ = Nephrology and Dialysis, 2000, vol. 2, no. 4. pp. 241–247 (in Russian).
23. Tsukamoto Y., Moriya R., Nagaba Y., Morishita T., Izumida I., Okubo M. Effect of administering calcium carbonate to treat secondary hyperparathyreoidism in nondialyzed patients with chronic renal failure. American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation, 1995, vol. 25, no. 6, pp. 879–886. https://doi.org/10.1016/0272-6386(95)90570-7
24. Mizumoto D., Watanabe Y., Fukuzawa Y., Yuzawa Y., Yamazaki C. Identification of risk factors of secondary hyperparathyreoidism undergoing longterm hemodialysis with vitamin D3. Nephrology Dialysis Transplantation, 1994, vol. 9, no. 12, pp. 1751–1758. https://doi.org/10.1093/ndt/9.12.1751
25. Goodman W. G., Coburn J. W. The use of 1,25-dihydroxyvitamin D3 in early renal falure. Annual Review of Medicine, 1992, vol. 43, pp. 227–237. https://doi.org/10.1146/annurev.med.43.1.227
26. Coen G., Mazzaferro S., Manni M., Fondi G., Perruzza I., Pasquali M., Taggi F. No acceleration and possibly slower progression of renal failure during calcitriol treatment in predialysis chronic renal failure. Nephrology Dialysis Transplantation, 1994, vol. 9, N 10, p. 1520. https://doi.org/10.1093/ndt/9.10.1520a
27. Herrman P., Ritz E., Schmidt-Gauk H., Schäfer I., Geyer J., Nonnast-Daniel B., Koch K.-M., Weber U., Hörl W., Haas-Wörle A., Kühn K., Bierther B., Schneider P. Comparison of intermittent and continuous oral administration of calcitriol in dialysis patients; a randomized prospective trial. Nephron, 1994, vol. 67, no. 1, pp. 48–53. https://doi.org/10.1159/000187887
28. Mazzaferro S., Pasquali M., Ballanti P., Bonucci E., Sanza P. D., Sardella D., Taggi F., Coen G. Intravenous versus oral calcitriol therapy in renal osteodystrophy: results of a prospective, pulsed and dose-comparable study. Mineral and Electrolyte Metabolism, 1994, vol. 20, no. 3, pp. 122–129.
29. Dressler R., Laut J., Lynn R. I., Ginsberg N. Long-term high dose intravenous calcitriol therapy in end-stage renal disease patients with severe secondary hyperparatireoidism. Clinical Nephrology, 1995, vol. 43 (5), pp. 324–331.
30. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney International Supplements, 2017, vol. 7, no. 1, pp. 1–59.
31. Foley R. N., Li S., Liu J., Gilbertson D. T., Chen Sh. C., Collins A. J. The fall and rise of parathyroidectomy in U. S. hemodialysis patients, 1992 to 2002. JASN: Journal of the American Society of Nephrology, 2004, vol. 16, no. 1, pp. 210–218. https://doi.org/10.1681/asn.2004020138
32. Hibi Y., Tominaga Y., Sato T., Katayama A., Haba T., Uchida K., Ichimori T., Numano M., Tanaka Y., Takagi H., Imai T., Funahashi H., Nakao A. Reoperation for renal hyperparathyroidism. World Journal of Surgery, 2002, vol. 26, no. 10, pp. 1301–1307. https://doi.org/10.1007/s00268-002-6731-8
33. Di Lullo L., Gorini A., Russo D., Santoboni A., Ronco C. Left Ventricular hypertrophy in chronic kidney disease patients: from pathophysiology to treatment. Cardiorenal Medicine, 2015, vol. 5, no. 4, pp. 254–266. https://doi.org/10.1159/000435838
34. Stanbury S. W., Lumb G. A., Nicholson W. F. Elective subtotal parathyroidectomy for renal hyperparathyroidism. Lancet (London, England), 1960, vol. 275, no. 7128, pp. 793–798. https://doi.org/10.1016/s0140-6736(60)90678-4
35. Ogg C. S. Total parathyroidectomy in treatment of secondary (renal) hyperparathyroidism. British Medical Journal, 1967, vol. 4, pp. 331–334. https://doi.org/10.1136/bmj.4.5575.331
36. Walgenbach S., Hommel G., Bernhard G., Köhler H., Wandel E., Gohlke F., Junginger T. Prospective Beo bachtungsstudie zur operativen Therapie des renalen Hyperparathyreoidismus. Chirurg, 1997, vol. 68, no. 2, pp. 147–153. https://doi.org/10.1007/s001040050165
37. Apetrii M., Goldsmith D., Nistor I., Siriopol D., Voroneanu L., Scripcariu D., Vervloet M., Covic A. Impact of surgical parathyroidectomy on chronic kidney disease-mineral and bone disorder (CKD-MBD) – a systematic review and metaanalysis. PloS ONE, 2017, vol. 12, no. 11, p. e0187025. https://doi.org/10.1371/journal.pone.0187025
38. Ivarsson K. M., Akaberi S., Isaksson E., Reihnér E., Rylance R., Prütz K. G., Clyne N., Almquist M. The effect of parathyroidectomy on patient survival in secondary hyperparathyroidism. Nephrology Dialysis Transplantation, 2015, vol. 30, no. 12, pp. 2027–2033. https://doi.org/10.1093/ndt/gfv334
39. Komaba H., Taniguchi M., Wada A., Iseki K., Tsubakihara Y., Fukagawa M. Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney International, 2015, vol. 88, no. 2, pp. 350–359. https://doi.org/10.1038/ki.2015.72
40. Conzo G., Perna A. F., Savica V., Palazzo A., Pietra C. D., Ingrosso D., Satta E., Capasso G., Santini L., Docimo G. Impact of parathyroidectomy on cardiovascular outcomes and survival in chronic hemodialysis patients with secondary hyperparathyroidism. A retrospective study of 50 cases prior to the calcimimetics era. BMC Surgery, 2013, vol. 13, suppl. 2, p. S4. https://doi.org/10.1186/1471-2482-13-s2-s4
41. Sharma J., Raggi P., Kutner N., Bailey J., Zhang R., Huang Y., Herzog Ch. A., Weber C. Improved long-term survival of dialysis patients after near-total parathyroidectomy. Journal of the American College of Surgeons, 2012, vol. 214, no. 4, pp. 400–407. https://doi.org/10.1016/j.jamcollsurg.2011.12.046
42. Goldenstein P. T., Elias R. M., de Freitas do Carmo L. P., Coelho F. O., Magalhães L. P., Antunes G. L., Custódio M. R., de Menezes Montenegro F. L., Titan S. M., Jorgetti V., Affonso Moysés R. M. Parathyroidectomy improves survival in patients with severe hyperparathyroidism: a comparative study. PloS ONE, 2013, vol. 8, no. 8, p. e68870. https://doi.org/10.1371/journal. pone.0068870
43. Komaba H., Taniguchi M., Wada A., Iseki K., Tsubakihara Y., Fukagawa M. Total parathyroidectomy improves survival of hemodialysis patients with secondary hyperparathyroidism. Journal of Nephrology, 2011, vol. 25, no. 5, pp. 755–763. https://doi.org/10.5301/jn.5000056
44. Kestenbaum B., Andress D. L., Schwartz S. M., Gillen D. L., Seliger S. L., Jadav P. R., Sherrard D. J., Stehman-Breen C. Survival following parathyroidectomy among United States dialysis patients. Kidney International, 2004, vol. 66, no. 5, pp. 2010–2016. https://doi.org/10.1111/j.1523-1755.2004.00972.x
45. Trombetti A., Stoermann C., Robert J. H., Herrmann F. R., Pennisi P., Martin P.-Y., Rizzoli R. Survival after para thyroidectomy in patients with end-stage renal disease and severe hyperparathyroidism. World Journal of Surgery, 2007, vol. 31, no. 5, pp. 1014–1021. https://doi.org/10.1007/s00268-006-0693-1
46. Ho L. Ch., Hung S. Y., Wang H. H., Kuo T. H., Chang Y. T., Tseng C. C., Wu J. L., Li C. Y., Wang J. D., Tsai Y. S., Sung J. M. Parathyroidectomy associates with reduced mortality in taiwanese dialysis patients with hyperparathyroidism: evidence for the controversy of current guidelines. Scientific Reports, 2016, vol. 6, art. 19150. https://doi.org/10.1038/srep19150
47. Moldovan D., Racasan S., Kacso I. M., Rusu C., Potra A., Bondor C., Patiu I. M., Gherman-Căprioară M. Survival after parathyroidectomy in chronic hemodialysis patients with severe secondary hyperparathyroidism. International Urology and Nephrology, 2015, vol. 47, no. 11, pp. 1871–1877. https://doi.org/10.1007/s11255-015-1106-x
48. Li W., Zhang M., Du S., Yu Y., Liu J., Zhang L., Yao L. Impact of parathyroidectomy on survival among haemodialysis patients: a prospective cohort study. Nephrology, 2016, vol. 21, no. 2, pp. 133–138. https://doi.org/10.1111/nep.12564
49. Costa-Hong V., Jorgetti V., Gowdak L. H., Moyses R. M., Krieger E. M., De Lima J. J. Parathyroidectomy reduces cardiovascular events and mortality in renal hyperparathyroidism. Surgery, 2007, vol. 142, no. 5, pp. 699–703. https://doi.org/ 10.1016/j.surg.2007.06.015
50. Dussol B., Morand P., Martinat C., Lombard E., Portugal H., Brunet Ph., von Berland Y. Influence of parathyroidectomy on mortality in hemodialysis patients: a prospective observational study. Renal Failure, 2007, vol. 29, no. 5, pp. 579–586. https://doi.org/10.1080/08860220701392447
51. Ma T.-L., Hung P.-H., Jong I.-Ch., Hiao Ch.-Y., Hsu Y.-H., Chiang P.-Ch., Guo Y.-R., Hung K.-Y. Parathyroidectomy is associated with reduced mortality in hemodialysis patients with secondary hyperparathyroidism. BioMed Research International, 2015, vol. 2015, pp. 1–7. https://doi.org/10.1155/2015/639587
52. Lin H.-Ch., Chen Ch.-L., Lin H.-S., Chou K.-J., Fang H.-Ch., Liu S.-I., Hsu Ch.-Y., Huang W.-Ch., Huang Ch.-W., Huang Ch. K., Chang T.-Y., Chang Y.-T., Lee P.-T. Parathyroidectomy improves cardiovascular outcome in nondiabetic dialysis patients with secondary hyperparathyroidism. Clinical Endocrinology, 2013, vol. 80, no. 4, pp. 508–515. https://doi.org/10.1111/cen.12333
53. Massry S. G., Smogorzewski M. Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia. Seminars in Nephrology, 1994, vol. 14, no. 3, pp. 219–231.
54. Chiu K. C., Chuang L.-M., Lee N. P., Ryu J. M., McGullam J. L., Tsai G. P., Saad M. F. Insulin sensitivity is inversely correlated with plasma intact parathyroid hormone level. Metabolism, 2000, vol. 49, no. 11, pp. 1501–1505. https://doi.org/10.1053/meta.2000.17708
55. Massry S. G., Alexiewicz J. M., Gaciong Z., Klinger M. Secondary hyperparathyroidism and the immune system in chronic renal failure. Seminars in Nephrology, 1991, vol. 11, no. 2, pp. 186–201.
56. Rao D. S., Shih M.-S., Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. New England Journal of Medicine, 1993, vol. 328, no. 3, pp. 171–175. https://doi.org/10.1056/ nejm199301213280304
57. Ballinger A. E., Palmer S. C., Nistor I., Craig J. C., Strippoli G. F. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database of Systematic Reviews. Available at: https://www.cochranelibrary.com/ cdsr/doi/10.1002/14651858.CD006254.pub2/full (accessed 20.09.2018).
58. Chertow G. M., Block G. A., Correa-Rotter R., Drüeke T. B., Floege J., Goodman W. G., Herzog C. A., Kubo Y., London G. M., Mahaffey K. W., Mix T. C., Moe S. M., Trotman M. L., Wheeler D. C., Parfrey P. S. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. New England Journal of Medicine, 2012, vol. 367, no. 26, pp. 2482–2494. https://doi.org/10.1056/nejmoa1205624
59. Malluche H. H., Monier-Faugere M.-C., Wang G, Frazão O. J. M., Charytan C., Coburn J. W., Coyne D. W., Kaplan M. R., Baker N., McCary L. C., Turner S. A., Goodman W. G. An assessment of cinacalcet HC1 effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clinical Nephrology, 2008, vol. 69, no. 4, pp. 269–278. https://doi.org/10.5414/cnp69269
60. Lien Y.-H. H., Silva A. L., Whittman D. Effects of cinacalcet on bone mineral density in patients with secondary hyper parathyroidism. Nephrology Dialysis Transplantation, 2005, vol. 20, no. 6, pp. 1232–1237. https://doi.org/10.1093/ndt/gfh829
61. Cunningham J., Danese M., Olson K., Klassen P., Chertow G. M. Effects of the calcimimetic cinacalcet HC1 on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney International, 2005, vol. 68, no. 4, pp. 1793–1800. https://doi.org/10.1111/j.1523-1755.2005.00596.x
62. Block G. A., Zaun D., Smits G., Persky M., Brillhart S., Nieman K., Liu J., St Peter W. L. Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney International, 2010, vol. 78, no. 6, pp. 578–589. https://doi.org/10.1038/ki.2010.167
63. Evenepoel P., Rodriguez M., Ketteler M. Laboratory abnormalities in CKD-MBD: markers, predictors, or mediators of disease? Seminars in Nephrology, 2014, vol. 34, no. 2, pp. 151–163. https://doi.org/10.1016/j.semnephrol.2014.02.007
64. Covic A., Goldsmith D. J., Georgescu G., Venning M. C., Ackrill P. Echocardiographic findings in long-term, longhour hemodialysis patients. Clinical Nephrology, 1996, vol. 45, no. 2, pp. 104–110.
65. Abdelhadi M., Nordenström J. Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 1998, vol. 83, no. 11, pp. 3845–3851. https://doi.org/10.1210/jc.83.11.3845
66. Chou F.-F., Chen J.-B., Lee Ch.-H., Chen S.-H., Sheen-Chen S.-M. Parathyroidectomy can improve bone mineral density in patients with symptomatic secondary hyperparathyroidism. Archives of Surgery, 2001, vol. 136, no. 9, pp. 1064–1068. https://doi.org/10.1001/archsurg.136.9.1064
67. Yano S., Sugimoto T., Tsukamoto T., Yamaguchi T., Hattori T., Sekita K.-I., Kaji H., Hattori S., Kobayashi A., Chihara K. Effect of parathyroidectomy on bone mineral density in hemodialysis patients with secondary hyperparathyroidism: possible usefulness of preoperative determination of parathyroid hormone level for prediction of bone regain. Hormone and Metabolic Research, 2003, vol. 35, no. 4, pp. 259–264. https://doi.org/10.1055/s-2003-39483
68. Rault R., Magnone M. The effect of parathyroidectomy on hematocrit and erythropoietin dose in patients on hemodialysis. ASAIO Journal, 1996, vol. 42, no. 2, p. 74. https://doi.org/10.1097/00002480-199603000-00278
69. Jemcov T. K., Petakov M., Bogdanovic A., Djukanovic L., Lezaic V. D. Parathyroidectomy and improving anemia. Archives of Surgery, 2008, vol. 143, no. 1, pp. 97–98. https://doi.org/10.1001/archsurg.2007.26
70. Chow T.-L., Chan T. T.-F., Ho Y.-W., Lam S.-H. Improvement of anemia after parathyroidectomy in Chinese patients with renal failure undergoing long-term dialysis. Archives of Surgery, 2007, vol. 142, no. 7, pp. 644–648. https://doi.org/10.1001/archsurg.142.7.644
71. Tzanno-Martins C., Futata E., Jorgetti V., Duarte A. J. S. Restoration of impaired T-cell proliferation after parathyroidectomy in hemodialysis patients. Nephron, 2000, vol. 84, no. 3, pp. 224–227. https://doi.org/10.1159/000045581
72. Yasunaga C., Nakamoto M., Matsuo K., Nishihara G., Yoshida T., Goya T. Effects of a parathyroidectomy on the immune system and nutritional condition in chronic dialysis patients with secondary hyperparathyroidism. American Journal of Surgery, 1999, vol. 178, no. 4, pp. 332–336. https://doi.org/10.1016/s0002-9610(99)00194-4
73. Van der Plas W. Y., Dulfer R. R., Engelsman A. F., Vogt L., de Borst M. H., van Ginhoven T. M., Kruijff S. Effect of parathyroidectomy and cinacalcet on quality of life in patients with end-stage renal disease-related hyperparathyroidism: a systematic review. Nephrology Dialysis Transplantation, 2017, vol. 32, N 11, pp. 1902–1908. https://doi.org/10.1093/ndt/gfx044
74. Tominaga Y. Current status of parathyroidectomy for secondary hyperparathyroidism in Japan. Clinical Kidney Journal, 2008, vol. 1, suppl. 3, pp. iii35–iii38. https://doi.org/10.1093/ndtplus/sfn085
75. Tentori F., Wang M., Bieber B. A., Karaboyas A., Li Y., Jacobson S. H., Andreucci V. E., Fukagawa M., Frimat L., Mendelssohn D. C., Port F. K., Pisoni R. L., Robinson B. M. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Clinical Journal of the American Society of Nephrology, 2014, vol. 10, no. 1, pp. 98–109. https://doi.org/10.2215/cjn.12941213
76. Kim S. M., Long J., Montez-Rath M. E., Leonard M. B., Norton J. A., Chertow G. M. Rates and outcomes of parathyroidectomy for secondary hyperparathyroidism in the United States. Clinical Journal of the American Society of Nephrology, 2016, vol. 11, no. 7, pp. 1260–1267. https://doi.org/10.2215/cjn.10370915
77. Farrington K., Covic A., Nistor I., Aucella F., Clyne N., De Vos L., Findlay A., Fouque D., Grodzicki T., Iyasere O., Jager K. J., Joosten H., Macias J. F., Mooney A., Nagler E., Nitsch D., Taal M., Tattersall J., Stryckers M., van Asselt D., Van den Noortgate N., van der Veer S., van Biesen W. Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR2): a summary document from the European Renal Best Practice Group. Nephrology Dialysis Transplantation, 2017, vol. 32. no. 1, pp. 9–16. https://doi.org/10.1093/ndt/gfw411
78. Goldsmith D., Covic A., Vervloet M., Cozzolino M., Nistor I. Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement. Nephrology Dialysis Transplantation, 2015, vol. 30, no. 5, pp. 698–700. https://doi.org/10.1093/ndt/gfv050
79. Sun Y., Cai H., Bai J., Zhao H., Miao Y. Endoscopic total parathiroidectomy and partial parathiroid tissue autotransplantation for patients with secondary hyperparathiroidism: a new surgical approach. World Journal of Surgery, 2009, vol. 33, no. 8, pp. 1674–1679. https://doi.org/10.1007/s00268-009-0086-3
80. Pisarenko A. M., Demidchik Yu. E., Il’inchik O. V., Khryshchanovich V. Ya., Kozlovskaya A. N., Kendenkov O. I., Balashova D. G. The surgical treatment results of secondary hyperparathyroidism with parathyroid autotransplantation application. Novosti khirurgii [Surgery news], 2014, vol. 22, no. 5, pp. 582–588 (in Russian).
81. Gourgiotis S., Moustafellos P., Stratopoulos C., Vougas V., Drakopoulos S., Hadjiyannakis E. Total parathyroidectomy with autotransplantation in patients with renal hyperparathyroidism: indications and surgical approach. Hormones (Athens), 2006, vol. 5, no. 4, pp. 270–275. https://doi.org/10.14310/horm.2002.11192
82. Chou F. F., Chi S. Y., Hsien K. C. Hypoparathiroidism after total parathireoidectomy plus subcutaneous autotransplantation for secondary hyperparathiroidism – any side effects? World Journal of Surgery, 2010, vol. 34, no. 10, pp. 2350–2354. https://doi.org/10.1007/s00268-010-0711-1
83. Sohal A. S, Gangji A. S., Crowther M. A., Treleaven D. Uremic bleeding: pathophysiology and clinical risk factors. Thrombosis Research, 2006, vol. 118, no. 3, pp. 417–422. https://doi.org/10.1016/j.thromres.2005.03.032
Review
For citations:
Pisarenka A.M. Surgical treatment of secondary hyperparathyroidism in patients with chronic kidney disease. Proceedings of the National Academy of Sciences of Belarus, Medical series. 2018;15(4):465-482. (In Russ.) https://doi.org/10.29235/1814-6023-2018-15-4-465-482
Views: 530
Email this article 